Close
CDMO Safety Testing 2026
Novotech

Thermo Fisher Scientific Collaborates to Introduce Fully Automated Cell Line Automation Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...
- Advertisement -

Thermo Fisher Scientific, the world leader in serving science, and Celltrio, a leading manufacturer of robotics-based solutions for the life sciences industry, have announced their collaboration to bring a fully automated cell culture system to biotherapeutics customers.

The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the critical unmet market need for high-throughput automated cell line culturing and maintenance. Celltrioโ€™s RoboCell systems distributed in Europe will now use Momentum software for work scheduling and data management. Thermo Fisher will also immediately take on exclusive responsibility for sales, installation, and support of the RoboCell system in Europe, with the possibility of extending into other geographies in the future.

โ€œCell line scale-up challenges have long stifled the full potential of biotherapy research. While researchers have been able to automate some aspects of cell line production, full automation has been well out of reach,โ€ said Hansjoerg Haas, senior director and general manager, laboratory automation, Thermo Fisher Scientific. โ€œBy collaborating with Celltrio, weโ€™re bringing together the capabilities that make fully automated cell line culturing a reality. With the ability to effectively scale processes, biotherapeutics customers can focus on getting their innovative therapies to patients, paving the way to a better, healthier world.โ€

Charlie Duncheon, CEO and co-founder, Celltrio, Inc. said, โ€œThe complementary expertise of Thermo Fisher and Celltrio offers a clear, powerful opportunity to help customers overcome a pressing roadblock. By offering Thermo Fisherโ€™s intuitive Momentum workflow scheduling software with Celltrioโ€™s end-to-end automation RoboCell platform, we can expand the RoboCell reach and amplify the impact of both solutions for biotherapeutics customers, benefitting the biopharma market and human health.โ€

With the Momentum workflow scheduling software, RoboCell users may define, execute, and monitor processes and workflows with an easy-to-use interface. The softwareโ€™s intelligent data-driven decision-making capabilities and bi-directional communication also enable secure connectivity and traceability while ensuring laboratories boost their performance.

Latest stories

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป